Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Groll, A. H.
Right arrow Articles by Walsh, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Groll, A. H.
Right arrow Articles by Walsh, T. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, 95-103
© 1999 The British Society for Antimicrobial Chemotherapy

Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics

Andreas H. Grolla, Corina E. Gonzaleza, Neelam Giria, Krystina Kligysa, William Lovea, Joanne Petera, Erwin Feuersteinb, John Bacherc, Stephen C. Piscitellid and Thomas J. Walsha,*

a Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute b Department of Radiology, Warren Grant Magnuson Clinical Center c Surgery Service, Veterinary Resources Program, National Center for Research Resources d Pharmacokinetics Research Laboratory, Pharmacy Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA

The activity of liposomal nystatin against invasive pulmonary aspergillosis was investigated in persistently neutropenic rabbits. Treatment groups included liposomal nystatin at dosages of 1, 2 and 4 mg/kg/day intravenously, or amphotericin B deoxycholate 1 mg/kg/day administered intravenously after normal saline loading. As compared with untreated controls, liposomal nystatin administered at 2 and 4 mg/kg/day prolonged survival and reduced fungus-mediated tissue injury and excess lung weight at post-mortem in a similar manner to amphotericin B. Although amphotericin B was superior in clearing infected lung tissue, treatment with all regimens of liposomal nystatin led to a significant reduction in pulmonary fungal tissue burden. During treatment, ultrafast CT-scan demonstrated ongoing resolution of pulmonary lesions at 2 and 4 mg/kg/day, but not at 1 mg/kg/day. With the exception of mild increases in blood urea nitrogen (BUN) and serum creatinine values during treatment at 2 and 4 mg/kg/day, which were similar to those found in amphotericin B-treated rabbits, liposomal nystatin was well tolerated. Preliminary pharmacokinetic studies in non-infected animals established linear drug disposition of liposomal nystatin in plasma over the investigated dosage range and peak plasma levels above the MIC for the test strain after multiple daily dosing for 7 days. Liposomal nystatin increased survival and provided reduced tissue injury, effective microbiological clearance and tolerable side effects in experimental pulmonary aspergillosis in persistently neutropenic rabbits, thus providing a rational basis for further investigations in clinical trials.

* Corresponding author. Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N240, 10 Center Drive, Bethesda, MD 20892, USA. Tel: +1-301-402-0023; Fax: +1-301-402-0575; E-mail: twalsh{at}exchange.nih.gov


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
E. Dannaoui, J. F. G. M. Meis, J. W. Mouton, P. E. Verweij, and the Eurofung Network
In vitro susceptibilities of Zygomycota to polyenes
J. Antimicrob. Chemother., May 1, 2002; 49(5): 741 - 744.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. H. Groll, D. Mickiene, K. Werner, R. Petraitiene, V. Petraitis, M. Calendario, A. Field-Ridley, J. Crisp, S. C. Piscitelli, and T. J. Walsh
Compartmental Pharmacokinetics and Tissue Distribution of Multilamellar Liposomal Nystatin in Rabbits
Antimicrob. Agents Chemother., April 1, 2000; 44(4): 950 - 957.
[Abstract] [Full Text]

Home page
 The OncologistHome page
C. C. Chiou, A. H. Groll, and T. J. Walsh
New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer
Oncologist, April 1, 2000; 5(2): 120 - 135.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
D. W. Denning and P. Warn
Dose Range Evaluation of Liposomal Nystatin and Comparisons with Amphotericin B and Amphotericin B Lipid Complex in Temporarily Neutropenic Mice Infected with an Isolate of Aspergillus fumigatus with Reduced Susceptibility to Amphotericin B
Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2592 - 2599.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
A. H. Groll, V. Petraitis, R. Petraitiene, A. Field-Ridley, M. Calendario, J. Bacher, S. C. Piscitelli, and T. J. Walsh
Safety and Efficacy of Multilamellar Liposomal Nystatin against Disseminated Candidiasis in Persistently Neutropenic Rabbits
Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2463 - 2467.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.